Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024.

Autor: Bryce AH; Department of Medical Oncology and Therapeutics Research, City of Hope Phoenix, Phoenix, Arizona, USA., Agarwal N; Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA., Beltran H; Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Hussain MH; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Evanston, Illinois, USA., Sartor O; Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA., Shore N; Carolina Urologic Research Center, Myrtle Beach, South Carolina, USA., Antonarakis ES; Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA., Armstrong AJ; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina, USA., Calais J; Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California, USA., Carducci MA; Hopkins Kimmel Cancer Center, Baltimore, Maryland, USA., Dorff TB; City of Hope Comprehensive Cancer Center, Duarte, California, USA., Efstathiou JA; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., Gleave M; Urological Sciences, Vancouver Prostate Center, University of British Columbia, Vancouver, British Columbia, Canada., Gomella LG; Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Higano C; Madrona Oncology, Seattle, Washington, USA., Hope TA; Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, USA., Iagaru A; Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California, USA., Morgans AK; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Morris DS; Urology Associates PC, Nashville, Tennessee, USA., Morris MJ; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Petrylak DP; Yale New Haven Health, New Haven, Connecticut, USA., Reiter RE; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California, USA., Rettig MB; Division of Hematology-Oncology, Department of Medicine, VA Greater Los Angeles, Los Angeles, California, USA.; Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California, USA.; Department of Urology, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California, USA., Ryan CJ; Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA., Sellinger SB; Advanced Urology Institute, Tallahassee, Florida, USA., Spratt DE; University Hospitals Seidman Cancer Center, Cleveland, Ohio, USA., Srinivas S; Division of Medical Oncology, Stanford University Medical Center, Stanford, California, USA., Tagawa ST; Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York, USA., Taplin ME; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA., Yu EY; Division of Hematology and Oncology, Department of Medicine, University of Washington and Fred Hutchinson Cancer Center, Seattle, Washington, USA., Zhang T; Division of Hematology and Oncology, Department of Internal Medicine, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA., McKay RR; Department of Urology, University of California San Diego, La Jolla, California, USA.; Department of Medicine, University of California San Diego, La Jolla, California, USA., Koo PJ; Banner MD Anderson Cancer Center, Phoenix, Arizona, USA., Crawford ED; Department of Urology, University of California San Diego, La Jolla, California, USA.

Publikováno v: Cancer [Cancer] 2025 Jan 01; Vol. 131 (1), pp. e35612. Date of Electronic Publication: 2024 Dec 01.

Defining Splicing Factor Requirements for Androgen Receptor Variant Synthesis in Advanced Prostate Cancer.

Autor: Walker L; Newcastle University Centre for Cancer, Newcastle upon Tyne, United Kingdom., Duncan R; Newcastle University Centre for Cancer, Newcastle upon Tyne, United Kingdom., Adamson B; Newcastle University Centre for Cancer, Newcastle upon Tyne, United Kingdom., Kendall H; Newcastle University Centre for Cancer, Newcastle upon Tyne, United Kingdom., Brittain N; Newcells Biotech, Newcastle upon Tyne, United Kingdom., Luzzi S; Newcastle University Biosciences Institute, International Centre for Life, Newcastle upon Tyne, United Kingdom., Jones D; Pierre-Fabre, Reading, United Kingdom., Chaytor L; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Peel S; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Crafter C; Early Oncology, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., O'Neill DJ; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Gaughan L; Newcastle University Centre for Cancer, Newcastle upon Tyne, United Kingdom.

Publikováno v: Molecular cancer research : MCR [Mol Cancer Res] 2024 Dec 03; Vol. 22 (12), pp. 1128-1142.

Comparative Transcriptomes of Canine and Human Prostate Cancers Identify Mediators of Castration Resistance.

Autor: Angel MR; Department of Pathology and Laboratory Medicine, Oregon Health and Science University, Portland, Oregon, USA., Séguin B; Flint Animal Cancer Center, Colorado State University, Fort Collins, Colorado, USA., Löhr CV; College of Veterinary Medicine, Oregon State University, Corvallis, Oregon, USA., Beer TM; Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA., Feliciano J; Veterinary Diagnostics & Imaging Consultants, Tualatin, Oregon, USA., Ramsey SA; College of Veterinary Medicine, Oregon State University, Corvallis, Oregon, USA.; College of Engineering, Oregon State University, Corvallis, Oregon, USA., Thomas GV; Department of Pathology and Laboratory Medicine, Oregon Health and Science University, Portland, Oregon, USA.; Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA.

Publikováno v: Veterinary and comparative oncology [Vet Comp Oncol] 2024 Dec; Vol. 22 (4), pp. 629-640. Date of Electronic Publication: 2024 Oct 07.

Targeting proliferating cell nuclear antigen enhances ionizing radiation-induced cytotoxicity in prostate cancer cells.

Autor: Lu S; Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA., Lamba M; Department of Radiation Oncology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA., Wang J; Department of Pathology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA., Dong Z; Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

Publikováno v: The Prostate [Prostate] 2024 Dec; Vol. 84 (16), pp. 1456-1467. Date of Electronic Publication: 2024 Sep 01.

L1CAM mediates neuroendocrine phenotype acquisition in prostate cancer cells.

Autor: Hsieh CL; The Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.; General Clinical Research Center, Chung Shan Medical University Hospital, Taichung, Taiwan.; Graduate Institute of Clinical Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan., Do AD; International Ph.D. Program for Translational Science, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.; Department of Physiology, Pathophysiology and Immunology, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam., Hsueh CY; The Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan., Raboshakga MO; International Ph.D. Program for Translational Science, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.; Department of Pre-Clinical Sciences, University of Limpopo, Sovenga, South Africa., Thanh TN; Department of Physiology, Pathophysiology and Immunology, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam., Tai TT; Department of Physiology, Pathophysiology and Immunology, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam., Kung HJ; Department of Biochemistry and Molecular Medicine, University of California Davis School of Medicine, University of California Davis Cancer Centre, Sacramento, California, USA.; Taipei Medical University, Taipei, Taiwan., Sung SY; The Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.; Graduate Institute of Clinical Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.; International Ph.D. Program for Translational Science, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.; Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.

Publikováno v: The Prostate [Prostate] 2024 Dec; Vol. 84 (16), pp. 1434-1447. Date of Electronic Publication: 2024 Aug 18.